Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron's Inmazeb Approval For Ebola Paves The Way In COVID-19

Executive Summary

The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.

You may also be interested in...



Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

Krystal Sees Success With Topical Gene Therapy In Debilitating Rare Skin Disorder

A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.

J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel